These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 14570880)
21. Hsp90: an emerging target for breast cancer therapy. Beliakoff J; Whitesell L Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596 [TBL] [Abstract][Full Text] [Related]
22. 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation. Niikura Y; Ohta S; Vandenbeldt KJ; Abdulle R; McEwen BF; Kitagawa K Oncogene; 2006 Jul; 25(30):4133-46. PubMed ID: 16501598 [TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831 [TBL] [Abstract][Full Text] [Related]
25. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112 [TBL] [Abstract][Full Text] [Related]
26. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Sugimoto K; Sasaki M; Isobe Y; Tsutsui M; Suto H; Ando J; Tamayose K; Ando M; Oshimi K Oncogene; 2008 May; 27(22):3091-101. PubMed ID: 18071310 [TBL] [Abstract][Full Text] [Related]
27. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Morgan MA; Parsels LA; Parsels JD; Mesiwala AK; Maybaum J; Lawrence TS Cancer Res; 2005 Aug; 65(15):6835-42. PubMed ID: 16061666 [TBL] [Abstract][Full Text] [Related]
28. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494 [TBL] [Abstract][Full Text] [Related]
29. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026 [TBL] [Abstract][Full Text] [Related]
30. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Huntoon CJ; Nye MD; Geng L; Peterson KL; Flatten KS; Haluska P; Kaufmann SH; Karnitz LM Cancer Res; 2010 Nov; 70(21):8642-50. PubMed ID: 20841485 [TBL] [Abstract][Full Text] [Related]
31. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371 [TBL] [Abstract][Full Text] [Related]
32. The Hsp90 chaperone complex as a novel target for cancer therapy. Goetz MP; Toft DO; Ames MM; Erlichman C Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371 [TBL] [Abstract][Full Text] [Related]
33. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Morgan MA; Parsels LA; Parsels JD; Lawrence TS; Maybaum J Cell Cycle; 2006 Sep; 5(17):1983-8. PubMed ID: 16931916 [TBL] [Abstract][Full Text] [Related]
34. HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Collis SJ; Barber LJ; Clark AJ; Martin JS; Ward JD; Boulton SJ Nat Cell Biol; 2007 Apr; 9(4):391-401. PubMed ID: 17384638 [TBL] [Abstract][Full Text] [Related]
35. ErbB2 degradation mediated by the co-chaperone protein CHIP. Zhou P; Fernandes N; Dodge IL; Reddi AL; Rao N; Safran H; DiPetrillo TA; Wazer DE; Band V; Band H J Biol Chem; 2003 Apr; 278(16):13829-37. PubMed ID: 12574167 [TBL] [Abstract][Full Text] [Related]
36. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966 [TBL] [Abstract][Full Text] [Related]
37. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity. Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314 [TBL] [Abstract][Full Text] [Related]
38. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Jin J; Shirogane T; Xu L; Nalepa G; Qin J; Elledge SJ; Harper JW Genes Dev; 2003 Dec; 17(24):3062-74. PubMed ID: 14681206 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796 [TBL] [Abstract][Full Text] [Related]
40. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]